Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ANGO | Common Stock | Options Exercise | $0 | +3.23K | +9.54% | $0.00 | 37.1K | Jul 7, 2022 | Direct | F1 |
transaction | ANGO | Common Stock | Tax liability | -$18.9K | -919 | -2.48% | $20.54 | 36.2K | Jul 7, 2022 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ANGO | Performance Right | Options Exercise | $0 | -6.45K | -100% | $0.00* | 0 | Jul 7, 2022 | Common Stock | 6.45K | Direct | F3 |
Id | Content |
---|---|
F1 | This acquisition of 3,233 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019. |
F2 | The exempt disposition of 919 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019. |
F3 | On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited. |